Literature DB >> 9881765

Alpha-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues.

S Ishii1, R Kase, H Sakuraba, C Taya, H Yonekawa, T Okumiya, Y Matsuda, K Mannen, M Takeshita, Y Suzuki.   

Abstract

We produced six transgenic mouse lines expressing human alpha-galactosidase (alpha-Gal) in order to evaluate its posttranslational modification. Among them, serum alpha-Gal activity increased 3000-fold in two transgenic mouse lines (TgN2 and TgN51), as compared to that in non-transgenic lines. The heart and liver of the TgN2 mouse expressed a high amount of transcript as well as high alpha-Gal activity. Its gene products in the heart and kidney were sensitive to endoglycosidase H digestion, but those in the spleen and liver were largely resistant. Glycopeptidase F treatment confirmed an identical molecular mass for the peptide moiety of the enzyme. We concluded that heterogeneous molecular mass of the gene products was caused by different degrees of posttranslational glycosylation in murine tissues.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9881765     DOI： 10.1023/a:1006915926732

Source DB:  PubMed          Journal:  Glycoconj J        ISSN： 0282-0080            Impact factor:   2.916


  22 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Mutation analysis in patients with the typical form of Anderson-Fabry disease.

Authors:  J P Davies; B G Winchester; S Malcolm
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

3.  A strategy to reveal high-frequency RFLPs along the human X chromosome.

Authors:  J Aldridge; L Kunkel; G Bruns; U Tantravahi; M Lalande; T Brewster; E Moreau; M Wilson; W Bromley; T Roderick
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

4.  Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease.

Authors:  H Sakuraba; A Oshima; Y Fukuhara; M Shimmoto; Y Nagao; D F Bishop; R J Desnick; Y Suzuki
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

5.  A case of Fabry's disease in a patient with no alpha-galactosidase A activity caused by a single amino acid substitution of Pro-40 by Ser.

Authors:  T Koide; M Ishiura; K Iwai; M Inoue; Y Kaneda; Y Okada; T Uchida
Journal:  FEBS Lett       Date:  1990-01-01       Impact factor: 4.124

6.  Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene.

Authors:  R Kornreich; D F Bishop; R J Desnick
Journal:  J Biol Chem       Date:  1990-06-05       Impact factor: 5.157

7.  Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs.

Authors:  R L Brinster; H Y Chen; M E Trumbauer; M K Yagle; R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

9.  Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms.

Authors:  D F Bishop; R J Desnick
Journal:  J Biol Chem       Date:  1981-02-10       Impact factor: 5.157

10.  Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.

Authors:  C M Eng; L A Resnick-Silverman; D J Niehaus; K H Astrin; R J Desnick
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025
View more
  2 in total

1.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

2.  Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy.

Authors:  Frank DeRosa; Lianne Smith; Yinghua Shen; Yan Huang; Jing Pan; Hongsheng Xie; Barak Yahalom; Michael W Heartlein
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.